Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2023; 12(04): 319-325
DOI: 10.1055/s-0043-1768920
Original Article
Breast Cancer

Androgen Receptor Expression in ER and PR Negative Breast Cancer—A Study from a Tertiary Hospital in Northern India

Sumeet Sidhu 
1   Christian Medical College and Hospital Ludhiana, Ludhiana, Punjab, India
,
Kanwardeep Singh Kwatra 
1   Christian Medical College and Hospital Ludhiana, Ludhiana, Punjab, India
,
Pamela Alice Kinsley 
1   Christian Medical College and Hospital Ludhiana, Ludhiana, Punjab, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Zoom Image
Sumeet Sidhu

Objectives Breast cancer is the leading cause of cancer-related deaths in women. Estrogen (ER) and progesterone receptor (PR) status and Her2 overexpression are major determinants in therapeutic decision making. Triple-negative breast cancers (TNBCs) have limited treatment options. Androgen receptor (AR) expression opens up therapeutic avenues for these patients. The aim of this article was to study the immunohistochemical expression of ARs in ER and PR Negative breast carcinomas and to correlate AR expression with various clinical, histopathological, and other immunohistochemical parameters.

Materials and Methods It is a cross-sectional study including 105 ER and PR Negative cases of breast carcinoma. Clinical parameters, histopathology, and immunohistochemical expression of AR, Her2, and Ki67 were analyzed in all cases.

Results AR expression was observed in 63.8% of ER and PR Negative breast cancers. In this group, AR expression was strongly associated with Her2 co-expression (89.2%) as compared to TNBCs (45.8%); p-value = 0.0002. Significant correlation was also observed between AR expression and tumor necrosis (p-value = 0.034) and postmenopausal status (p = 0.007).

Conclusion Our study shows that significant proportion of ER and PR Negative breast carcinomas (ER- PR- Her2+ and TNBCs) show AR expression. We strongly recommend routine evaluation of all hormone receptor-negative breast carcinomas for AR status by immunohistochemistry.

Keywords

androgen - breast carcinoma - estrogen - Her2 - TNBC

Authors' Contributions

Kanwardeep Kwatra, Pamela Alice Kinsley, and Sumeet Sidhu helped in planning and conceptualization and designing. Sumeet Sidhu and Kanwardeep Kwatra conducted and reported the study and analyzed and interpreted the data. Sumeet Sidhu acquired the data.




Publication History

Article published online:
29 May 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 GLOBOCAN 2020: Cancer incidence and mortality statistics worldwide and by region [Internet]. IARC WHO 2020 . [cited 2021 November 25]. Accessed April 19, 2023 at: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf
    PubMedSearch in Google Scholar
  • 2 Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 2016; 7 (10) 1281-1294
    CrossrefPubMedSearch in Google Scholar
  • 3 Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol 2014; 5 (03) 382-392
    CrossrefPubMedSearch in Google Scholar
  • 4 Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 2010; 23 (Suppl. 02) S52-S59
    CrossrefPubMedSearch in Google Scholar
  • 5 Piccart-Gebhart MJ, Procter M, Leyland-Jones B. et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16) 1659-1672
    CrossrefPubMedSearch in Google Scholar
  • 6 Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 Update. Arch Pathol Lab Med 2016; 140 (08) 806-814
    CrossrefPubMedSearch in Google Scholar
  • 7 Liao J, Gallas M, Pegram M, Slingerland J. Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Med Press) 2010; 2: 79-91
    PubMedSearch in Google Scholar
  • 8 Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther 2019; 199: 30-57
    CrossrefPubMedSearch in Google Scholar
  • 9 Schick J, Ritchie RP, Restini C. Breast cancer therapeutics and biomarkers: past, present, and future approaches. Breast Cancer (Auckl) 2021; 15: 1178223421995854
    CrossrefPubMedSearch in Google Scholar
  • 10 Iacopetta D, Rechoum Y, Fuqua SA. The role of androgen receptor in breast cancer. Drug Discov Today Dis Mech 2012; 9 (1-2): e19-e27
    CrossrefPubMedSearch in Google Scholar
  • 11 Sutton LM, Cao D, Sarode V. et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol 2012; 138 (04) 511-516
    CrossrefPubMedSearch in Google Scholar
  • 12 Lehmann BD, Bauer JA, Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121 (07) 2750-2767
    CrossrefPubMedSearch in Google Scholar
  • 13 Bozovic-Spasojevic I, Zardavas D, Brohée S. et al. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res 2017; 23 (11) 2702-2712
    CrossrefPubMedSearch in Google Scholar
  • 14 Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011; 24 (07) 924-931
    CrossrefPubMedSearch in Google Scholar
  • 15 Vera-Badillo FE, Templeton AJ, de Gouveia P. et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106 (01) djt319
    CrossrefPubMedSearch in Google Scholar
  • 16 Lakis S, Kotoula V, Eleftheraki AG. et al. The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast 2014; 23 (03) 234-243
    CrossrefPubMedSearch in Google Scholar
  • 17 Lim E, Ni M, Cao S, Hazra A, Tamimi RM, Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Curr Breast Cancer Rep 2014; 6 (02) 71-78
    CrossrefPubMedSearch in Google Scholar
  • 18 Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch 2010; 457 (04) 467-476
    CrossrefPubMedSearch in Google Scholar
  • 19 Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003; 120 (05) 725-731
    CrossrefPubMedSearch in Google Scholar
  • 20 Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. Am J Cancer Res 2014; 4 (04) 353-368
    PubMedSearch in Google Scholar
  • 21 Park S, Koo JS, Kim MS. et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 2011; 22 (08) 1755-1762
    CrossrefPubMedSearch in Google Scholar
  • 22 Peters AA, Buchanan G, Ricciardelli C. et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69 (15) 6131-6140
    CrossrefPubMedSearch in Google Scholar
  • 23 Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008; 10 (06) 542-548
    CrossrefPubMedSearch in Google Scholar
  • 24 Ni M, Chen Y, Fei T. et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev 2013; 27 (07) 734-748
    CrossrefPubMedSearch in Google Scholar
  • 25 Gerratana L, Basile D, Buono G. et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev 2018; 68: 102-110
    CrossrefPubMedSearch in Google Scholar
  • 26 Wardley A, Cortes J, Provencher L. et al. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat 2021; 187 (01) 155-165
    CrossrefPubMedSearch in Google Scholar